Esmethadone-HCl (REL-1017): a promising rapid antidepressant
European Archives of Psychiatry and Clinical Neuroscience · 2023-10 · 273 (7) · 1463-1476
DOI: 10.1007/s00406-023-01571-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Archives of Psychiatry and Clinical Neuroscience, online erschienen am 08.03.2023. Verfasst von Maurizio Fava und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Massachusetts General Hospital, Boston, MA, 02114, USA. Hauptthemen laut MEDLINE: Major Depressive Disorder, Alzheimer Disease. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Relmada Therapeutics.
Abstract (Originalsprache)
This review article presents select recent studies that form the basis for the development of esmethadone into a potential new drug. Esmethadone is a promising member of the pharmacological class of uncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonists that have shown efficacy for major depressive disorder (MDD) and other diseases and disorders, such as Alzheimer’s dementia and pseudobulbar affect. The other drugs in the novel class of NMDAR antagonists with therapeutic uses that are discussed for comparative purposes in this review are esketamine, ketamine, dextromethorphan, and memantine. We present in silico, in vitro, in vivo, and clinical data for esmethadone and other uncompetitive NMDAR antagonists that may advance our understanding of the role of these receptors in neural plasticity in health and disease. The efficacy of NMDAR antagonists as rapid antidepressants may advance our understanding of the neurobiology of MDD and other neuropsychiatric diseases and disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Massachusetts General Hospital, Boston, MA, 02114, USA.
- Department of Psychiatry, VAMC (SD), University of California, San Diego, La Jolla, CA, 92093, USA.
- Neuroscience Education Institute, Carlsbad, CA, 92008, USA.
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, 35122, Padua, Italy.
- In Vitro Pharmacology Department, Aptuit, an Evotec Company, 37135, Verona, Italy.
- Department of Biomedical Sciences, University of Padua, 35122, Padua, Italy.
Förderung
- Relmada Therapeutics
Zitieren
APA
Fava, M., Stahl, S. M., De Martin, S., Mattarei, A., Bettini, E., Comai, S., Alimonti, A., Bifari, F., Pani, L., Folli, F., Guidetti, C., Furlan, A., Sgrignani, J., Locatelli, P., Cavalli, A., O'Gorman, C., Traversa, S., Inturrisi, C. E., Pappagallo, M., & Manfredi, P. L. (2023). Esmethadone-HCl (REL-1017): a promising rapid antidepressant. European Archives of Psychiatry and Clinical Neuroscience, 273(7), 1463-1476. https://doi.org/10.1007/s00406-023-01571-4
Vancouver
Fava M, Stahl SM, De Martin S, Mattarei A, Bettini E, Comai S, et al. Esmethadone-HCl (REL-1017): a promising rapid antidepressant. European Archives of Psychiatry and Clinical Neuroscience. 2023;273(7):1463-1476. doi:10.1007/s00406-023-01571-4
BibTeX
@article{Fava2023,
author = {Fava, Maurizio and Stahl, Stephen M and De Martin, Sara and Mattarei, Andrea and Bettini, Ezio and Comai, Stefano and Alimonti, Andrea and Bifari, Francesco and Pani, Luca and Folli, Franco and Guidetti, Clotilde and Furlan, Alberto and Sgrignani, Jacopo and Locatelli, Patrizia and Cavalli, Andrea and O'Gorman, Cedric and Traversa, Sergio and Inturrisi, Charles E and Pappagallo, Marco and Manfredi, Paolo L},
title = {Esmethadone-HCl (REL-1017): a promising rapid antidepressant},
journal = {European Archives of Psychiatry and Clinical Neuroscience},
year = {2023},
volume = {273},
number = {7},
pages = {1463--1476},
doi = {10.1007/s00406-023-01571-4}
}
EUVIMED